Literature DB >> 26227834

Macular ischemia and outcome of vitrectomy for diabetic macular edema.

Jaeryung Kim1,2, Se Woong Kang3, Dong Hoon Shin2, Sang Jin Kim2, Ga Eun Cho2.   

Abstract

PURPOSE: To investigate the effect of vitrectomy on the treatment of diabetic macular edema (DME) refractory to nonsurgical therapies and to determine the preoperative prognostic factors related to surgical outcomes.
METHODS: Seventy-seven eyes from 74 patients who had undergone vitrectomy and macular photocoagulation 2 weeks after vitrectomy for nontractional DME refractory to anti-vascular endothelial growth factor or steroid injection and/or macular grid/focal photocoagulation were included. The eyes were divided into the responsive group (group 1) and the unresponsive group (group 2) according to the postoperative changes in central subfield thickness (CST). The changes in best-corrected visual acuity (BCVA) and CST were compared. Potential preoperative predictors including the size of the foveal avascular zone (FAZ) were assessed.
RESULTS: In group 1 (N = 51), the mean logarithm of the minimum angle of resolution BCVAs at baseline was 0.60 ± 0.30; 6 months after vitrectomy, 0.47 ± 0.28 (vs. baseline, p < 0.001); 12 months after vitrectomy, 0.38 ± 0.28 (vs. baseline, p < 0.001). However, in group 2 (N = 26), no significant change in BCVA was noted. Among the preoperative factors, only the size of the FAZ showed a significant difference between the two groups (0.45 ± 0.17 mm(2) in group 1 vs. 0.59 ± 0.26 mm(2) in group 2; p = 0.020). The enlarged FAZ was also significantly correlated with worse BCVA at the postoperative 6-month follow-up (r = 0.256, p = 0.025).
CONCLUSIONS: Vitrectomy is an effective treatment modality for DME refractory to nonsurgical therapies, especially in cases without enlarged FAZ. Preoperative evaluation of the perfusion status of the macula seems helpful to selecting candidates for vitrectomy.

Entities:  

Keywords:  Diabetic macular edema; Foveal avascular zone; Macular ischemia; Pars plana vitrectomy

Mesh:

Year:  2015        PMID: 26227834     DOI: 10.1007/s10384-015-0402-4

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  42 in total

1.  Triple therapy of vitrectomy, intravitreal triamcinolone, and macular laser photocoagulation for intractable diabetic macular edema.

Authors:  Se Woong Kang; Sung Chul Park; Hee Yoon Cho; Jae Hoon Kang
Journal:  Am J Ophthalmol       Date:  2007-10-15       Impact factor: 5.258

2.  The therapeutic effects of retinal laser treatment and vitrectomy. A theory based on oxygen and vascular physiology.

Authors:  E Stefánsson
Journal:  Acta Ophthalmol Scand       Date:  2001-10

3.  The influence of the photoreceptor-RPE complex on the inner retina. An explanation for the beneficial effects of photocoagulation.

Authors:  J J Weiter; R Zuckerman
Journal:  Ophthalmology       Date:  1980-11       Impact factor: 12.079

4.  Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.

Authors:  Michael J Elman; Neil M Bressler; Haijing Qin; Roy W Beck; Frederick L Ferris; Scott M Friedman; Adam R Glassman; Ingrid U Scott; Cynthia R Stockdale; Jennifer K Sun
Journal:  Ophthalmology       Date:  2011-04       Impact factor: 12.079

5.  Foveal avascular zone in diabetic retinopathy: quantitative vs qualitative assessment.

Authors:  J Conrath; R Giorgi; D Raccah; B Ridings
Journal:  Eye (Lond)       Date:  2005-03       Impact factor: 3.775

6.  Effects of macular ischemia on the outcome of intravitreal bevacizumab therapy for diabetic macular edema.

Authors:  Eun Jee Chung; Mi In Roh; Oh Woong Kwon; Hyoung Jun Koh
Journal:  Retina       Date:  2008 Jul-Aug       Impact factor: 4.256

7.  Diabetic maculopathy. A critical review highlighting diffuse macular edema.

Authors:  G H Bresnick
Journal:  Ophthalmology       Date:  1983-11       Impact factor: 12.079

8.  Retinal microcirculation in patients with diabetes mellitus: dynamic and morphological analysis of perifoveal capillary network.

Authors:  O Arend; S Wolf; F Jung; B Bertram; H Pöstgens; H Toonen; M Reim
Journal:  Br J Ophthalmol       Date:  1991-09       Impact factor: 4.638

9.  The effects of macular ischemia on visual acuity in diabetic retinopathy.

Authors:  Dawn A Sim; Pearse A Keane; Javier Zarranz-Ventura; Simon Fung; Michael B Powner; Elise Platteau; Catey V Bunce; Marcus Fruttiger; Praveen J Patel; Adnan Tufail; Catherine A Egan
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-03-28       Impact factor: 4.799

10.  Combined vitrectomy and intravitreal injection versus combined laser and injection for treatment of intractable diffuse diabetic macular edema.

Authors:  Ahmed M Saeed
Journal:  Clin Ophthalmol       Date:  2013-02-14
View more
  4 in total

Review 1.  Management of diabetic macular edema in Japan: a review and expert opinion.

Authors:  Hiroko Terasaki; Yuichiro Ogura; Shigehiko Kitano; Taiji Sakamoto; Toshinori Murata; Akito Hirakata; Tatsuro Ishibashi
Journal:  Jpn J Ophthalmol       Date:  2017-12-05       Impact factor: 2.447

2.  Three-year outcomes of vitrectomy combined with intraoperative dexamethasone implantation for non-tractional refractory diabetic macular edema.

Authors:  Sungsoon Hwang; Se Woong Kang; Kyung Tae Kim; Hoon Noh; Sang Jin Kim
Journal:  Sci Rep       Date:  2021-01-14       Impact factor: 4.379

3.  Pars Plana Vitrectomy versus Intravitreal Injection of Ranibizumab in the Treatment of Diabetic Macular Edema Associated with Vitreomacular Interface Abnormalities.

Authors:  Hassan Elkayal; Ahmed M Bedda; Hesham El-Goweini; Ahmed A Souka; Amir Ramadan Gomaa
Journal:  J Ophthalmol       Date:  2021-01-12       Impact factor: 1.909

4.  The association between different hypoglycemic regimens and postoperative diabetic macular edema after vitrectomy in the Japanese patients with proliferative diabetic retinopathy.

Authors:  Chunyan Lei; Yun Zhang; Meixia Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-22       Impact factor: 6.055

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.